search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Specific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults


- candidate number3871
- NTR NumberNTR1419
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR25-aug-2008
- Secondary IDsLTR138 Laboratory for Vaccine Preventable Diseases (LTR)
- Public TitleSpecific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults
- Scientific TitleSpecific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults
- ACRONYMB-cell Memory After MenC Vaccination
- hypothesisA single MenC polysaccharide-protein conjugate vaccination was introduced into the National Vaccination Program (RVP) at the age of 14 months in 2002. Furthermore in 2002, in a large national campaign all children and adolescents between the age of 1 and 18 years received one dose of MenC conjugate vaccine.
In the following years it will become clear how effective MenC vaccination is in the long term. Long term protection is mainly based on memory after vaccination or natural infection. In the Netherlands MenC memory is induced by a single vaccination.
The cellular and molecular pathways for induction of MenC memory (or any other protein conjugated polysaccharide for that matter) are not totally clear.
- Healt Condition(s) or Problem(s) studiedInfectious diseases, MenC polysaccharide-protein conjugate vaccination, Memory B cells, Meningitis
- Inclusion criteria1. Good general health;
2. Provision of written informed consent;
3. Adherent to protocol, and available during the study period
- Exclusion criteria1. Severe acute (infectious) illness of fever (>38.5C) within 2 weeks before vaccination;
2. Present evidence of serious disease(s) demanding medical treatment that might interfere the results of the study;
3. Known or suspected allergy to any of the vaccine components (by medical history);
4. Known or suspected immune deficiency;
5. History of any neurologic disorder, including epilepsy;
6. Previous administration of plasma products (including immunoglobulins) within the last 6 months;
7. Pregnancy
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 4-mei-2007
- planned closingdate1-dec-2008
- Target number of participants21
- Interventions- One group receives a primary MenC conjugate vaccination (Neisvac-C).
- The other two groups receive either a conjugate MenC (Neisvac-C) or polysaccharide MenC booster vaccination (Meningovax A+C).
Blood will be drawn before and several time points after vaccination.
- Primary outcome- How long does B-cell memory persist after a single conjugate MenC vaccination in adults and which cells are involved?
- Secondary outcome- How long do serum SBA titers persist in time after a single vaccination with the conjugate MenC vaccine?
- Despite decline of antibody concentrations in the years after vaccination, do memory B-cells persist?
- Antibody kinetics, it is important to follow the rise of antibody titers after vaccination:
o How long will it take before serum IgG antibodies are detectable and/or rise after primary- or booster vaccination?
o What is the avidity of serum IgG antibodies compared to the primary and booster vaccination?
- In what time period after primary vaccination with MenC are memory B-cells formed and how rapidly do memory B-cells expand after booster vaccination?
- Are there differences (antibody titer levels, IgG subclass distribution and serum antibody avidity) in booster responses between a booster vaccination using the conjugate MenC vaccine or plain serogroup C capsular polysaccharide .
- TimepointsStudy Calendar:
Day 0: Pre-vaccination blood sample (20-30ml)
Day 0: Vaccination with MenC conjugate vaccine or Men(A)C polysaccharide vaccine
Day 1: Blood sampling (20-30ml)
Day 3: Blood sampling (20-30ml)
Day 5: Blood sampling (20-30ml)
Day 7: Blood sampling (20-30ml)
Day 9: Blood sampling (20-30ml)
Day 11: Blood sampling (20-30ml)
Day 14: Blood sampling (20-30ml)
Day 28: Blood sampling (20-30ml)
- Trial web siteN/A
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIESPhD G. Berbers
- CONTACT for SCIENTIFIC QUERIESPhD G. Berbers
- Sponsor/Initiator National Institute for Public Health and the Environment (RIVM), Laboratory for Vaccine Preventable Diseases (LTR)
- Funding
(Source(s) of Monetary or Material Support)
National Institute of Public Health and Environmental Protection (RIVM), Laboratory for Vaccine Preventable Diseases (LTR)
- PublicationsN/A
- Brief summaryWe will evaluate the kinetics of circulating antibodies, investigating the presence of MenC specific plasma and memory B lymphocytes and antibody production after polyclonal stimulation of peripheral blood mononuclear cells (PBMC) in vitro. Vaccine responses after a single or multiple MenC vaccinations (booster with MenC conjugate or with polysaccharide vaccine) will be compared with natural immunity without previous vaccinations. It will be interesting to investigate if the polysaccharide vaccine is capable of inducing a booster response. And if so, it will be of interest to characterize this response and compare it to the booster response induced by the conjugate vaccine.
- Main changes (audit trail)
- RECORD25-aug-2008 - 29-sep-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl